论文部分内容阅读
目的观察自体外周血造血干细胞移植(APBSCT)治疗恶性血液病的初期疗效。方法恶性血液病患者20例,其中急性白血病3例,浆细胞白血病1例,非霍奇金淋巴瘤8例,霍奇金淋巴瘤3例,多发性骨髓瘤5例。动员方案为米托蒽醌+长春新碱+激素+依托波苷方案化疗(MOEP方案)+粒细胞集落刺激因子。经3-6d采集,获得单个核细胞(MNC)中位数为(7.23±2.27)×108/kg,CD34+细胞(4.37±2.72)×106/kg。结果所有患者移植后均重建造血。WBC>2.0×109/L,PLT>20×109/L,分别为(12.04±1.76)d,(16.55±2.31)d。4例在移植6个月内死于复发,其余16例均无病存活6-55个月。结论 APBSCT对恶性血液病是一种安全有效的治疗方法。
Objective To observe the initial effect of autologous peripheral blood stem cell transplantation (APBSCT) in the treatment of hematologic malignancies. Methods Twenty patients with hematologic malignancies were involved, including 3 acute leukemia, 1 plasmacytoid leukemia, 8 non-Hodgkin’s lymphoma, 3 Hodgkin lymphoma and 5 multiple myeloma. Mobilization program mitoxantrone + vincristine + hormone + etoposide regimen chemotherapy (MOEP regimen) + granulocyte colony stimulating factor. The median number of mononuclear cells (MNC) was (7.23 ± 2.27) × 108 / kg and CD34 + cells (4.37 ± 2.72) × 106 / kg after 3-6 days. Results All patients underwent reconstruction of hematopoiesis after transplantation. WBC> 2.0 × 109 / L and PLT> 20 × 109 / L, respectively (12.04 ± 1.76) d and (16.55 ± 2.31) d. Four patients died of recurrence within 6 months after transplantation, and the remaining 16 patients survived without disease for 6-55 months. Conclusion APBSCT is a safe and effective treatment for hematologic malignancies.